Literature DB >> 20656751

Renal involvement in Castleman disease.

Khalil El Karoui1, Vincent Vuiblet, Daniel Dion, Hassan Izzedine, Joelle Guitard, Luc Frimat, Michel Delahousse, Philippe Remy, Jean-Jacques Boffa, Evangéline Pillebout, Lionel Galicier, Laure-Hélène Noël, Eric Daugas.   

Abstract

BACKGROUND: Castleman disease (CD), or angiofollicular lymph-node hyperplasia, is an atypical lymphoproliferative disorder with heterogeneous clinical manifestations. Renal involvement in CD has been described in only single-case reports, which have included various types of renal diseases.
METHODS: Nineteen patients with histologically documented CD and renal biopsies available were included. Clinical features and renal histological findings were reviewed, and the available samples were immunolabelled with anti-vascular endothelial growth factor (VEGF) antibody.
RESULTS: Nineteen CD cases were identified: 89% were multicentric, and 84% were of the plasma-cell or mixed type. Four cases (21%) were associated with human immunodeficiency virus (HIV) infection. Among HIV-negative patients, two main patterns of renal involvement were found: (i) a small-vessel lesions group (SVL) (60%) with endotheliosis and glomerular double contours in all patients and with superimposed glomerular/arteriolar thrombi or mesangiolysis in most; and (ii) AA amyloidosis (20%). Renal histology was more heterogeneous among HIV-positive patients. Decreases in glomerular VEGF were observed only in some patients with SVL, whereas VEGF staining was normal in all other histological groups. Interestingly, glomerular VEGF loss associated with SVL was correlated with plasma C-reactive protein levels, a marker of CD activity.
CONCLUSIONS: Small-vessel lesions are the most frequent renal involvement in CD, whereas loss of glomerular VEGF is correlated with CD activity and could have a role in SVL pathophysiology.

Entities:  

Mesh:

Year:  2010        PMID: 20656751     DOI: 10.1093/ndt/gfq427

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  33 in total

1.  Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.

Authors:  Lucie M Turcotte; Colleen K Correll; Robyn C Reed; Christopher L Moertel
Journal:  Pediatr Blood Cancer       Date:  2013-09-09       Impact factor: 3.167

2.  Multicentric Castleman's disease with renal amyloidosis and mesangial proliferative glomerulonephritis: a case report.

Authors:  Zhicheng Tan; Lihua Wang; Chen Wang; Lifang Gao; Yanrong Yang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Renal complications of Castleman's disease: report of two cases and analysis of 75 cases.

Authors:  Xiang-Gui Yuan; Wen Hu; Fei-Fei Chen; Bin-Feng Huang; Xiao-Ying Zhao
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

4.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

5.  Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome.

Authors:  Tamami Fujiki; Suguru Hirasawa; Seishi Watanabe; Shunsuke Iwamoto; Ryoichi Ando
Journal:  CEN Case Rep       Date:  2017-03-07

6.  A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy.

Authors:  Khalil El Karoui; Gary S Hill; Alexandre Karras; Christian Jacquot; Luc Moulonguet; Olivier Kourilsky; Véronique Frémeaux-Bacchi; Michel Delahousse; Jean-Paul Duong Van Huyen; Alexandre Loupy; Patrick Bruneval; Dominique Nochy
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

7.  TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report.

Authors:  Shoko Noda-Narita; Keiichi Sumida; Akinari Sekine; Junichi Hoshino; Koki Mise; Tatsuya Suwabe; Noriko Hayami; Masayuki Yamanouchi; Toshiharu Ueno; Hiroki Mizuno; Masahiro Kawada; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi; Kenichi Ohashi; Takeshi Fujii; Yoshifumi Ubara
Journal:  CEN Case Rep       Date:  2018-02-21

8.  Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.

Authors:  Hirotaka Saito; Kenichi Tanaka; Momoko Fujiwara; Tsuyoshi Iwasaki; Tokutaro Numata; Akira Oda; Makoto Kanno; Mizuko Tanaka; Masaaki Eiro; Mamoru Satoh; Junichiro James Kazama
Journal:  CEN Case Rep       Date:  2019-05-10

9.  Focal segmental glomerulosclerosis associated with cutaneous and systemic plasmacytosis.

Authors:  Shinsuke Isobe; Naro Ohashi; Naoko Katahashi; Sayaka Ishigaki; Naoko Tsuji; Takayuki Tsuji; Akihiko Kato; Yoshihide Fujigaki; Akira Shimizu; Hideo Yasuda
Journal:  CEN Case Rep       Date:  2017-09-22

10.  Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome.

Authors:  Toshikazu Ozeki; Masashi Tsuji; Junichiro Yamamoto; Chisato Shigematsu; Shoichi Maruyama
Journal:  CEN Case Rep       Date:  2018-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.